Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Nov 11, 2021 10:51am
275 Views
Post# 34114840

RE:RE:RE:RE:RE:RE:Just a warning.

RE:RE:RE:RE:RE:RE:Just a warning.
Rawrasaurus wrote:
Most of the people who still believe in the company left this site due to trolls. Mugs hasn't gone anywhere and we all talk every couple days on the other platform. Until things start going on the new trials, there's nothing to discuss. Feel free to keep bashing amongst yourselves though.


Exactly Raw !

As the bashers are too busy bashing - we've been doing risk assessments and getting questions answered - to understand what the value really is here.

Not sure why the ones who want to blame are also the ones who are interested so intimately in me - that makes no sense at all but neither does their logic and their understanding.  Hahaha - love it !

At this point , we better understand why attacking acute now makes sense and how it's one of those "kill 2 birds with one stone" type situations.

We better understand the multi-faceted liver issues at play.

We also see the risk profile for acute vs. chronic - and - the type of tools required in the toolbox in order to secure winning regimens.  Not just related to OTENA but to all acute/chronic drugs in the pipeline.

IMO - everything is still in play. 
There's always risk - but still in play.
That's what you get here - so don't expect any guarantees.

You want guarantees - put your money in a GIC.  Hahaha !

: )


<< Previous
Bullboard Posts
Next >>